

I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office on the date shown below:

AMENDMENT UNDER 37 CFR 1.111
Examining Group 1625
Patent Application
Docket No. GJE-7230

January 29, 2008

David R. Saliwanchik
David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Taofig A. Solola, Ph.D., JD.
Art Unit : 1625
Applicants : John Gary Montana *et al.*
Serial No. : 10/531,333
Conf. No. : 7930
Filed : April 14, 2005
For : Heterocyclic Silicon Compounds and Their Use in the Treatment of Diseases or Conditions Associated with GNRH (Gonadotropin-Releasing Hormone)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

AMENDMENT UNDER 37 CFR 1.111

Sir:

A two month extension of time, through and including January 29, 2008, is being authorized with the electronic filing of this paper.

In response to the Office Action dated August 29, 2007, please amend the subject application as follows:

Amendments to the Claims are reflected in the listing of claims beginning on page 2 of this paper.

Remarks/Arguments follow the amendment sections of this paper.